MediSpend Acquires Real Life Sciences to Enhance Compliance Solutions for Life Sciences Industry

MediSpend, a global technology company based in Portsmouth, N.H., has announced its acquisition of Real Life Sciences (RLS), a leader in advanced anonymization solutions for clinical trial and other data, reinforcing its commitment to expanding its presence and capabilities in the Governance, Risk and Compliance (GRC) space. The acquisition of RLS bolsters MediSpend's ability to support life sciences companies and contract research organizations (CROs) in navigating complex regulatory requirements to disclose clinical trial results data while protecting participant privacy and intellectual property.

RLS's flagship platform, RLS Protect, delivers industry-leading solutions for anonymization and redaction, enabling organizations to confidently disclose clinical trial data with health authorities, research partners, internal teams and publications while safeguarding participant privacy and commercially confidential information. Real Life Sciences' offerings align with MediSpend's mission to empower life sciences companies with technology that drives growth, compliance and transparency.

The acquisition expands the company's reach into research and development (R&D) compliance and the protection of vital intellectual property, as well as enhances its ability to serve a broader market and support clients with tools to meet evolving global regulatory demands. RLS' solutions address compliance requirements across major regulatory bodies, including EMA (EU) 536/2014, EMA Clinical Data Publication Policy 0070, Health Canada Public Release of Clinical Information (PRCI), FDA disclosure mandates and more.

With the addition of RLS, MediSpend strengthens its portfolio of solutions, enabling clients to manage compliance and regulations comprehensively from commercial operations to R&D. This transformative milestone in Real Life Sciences' growth journey empowers them to further enhance their solutions for life sciences organizations as they navigate evolving global regulatory requirements for clinical transparency, data sharing and participant privacy.

Read more about the aquisition here